Form 8-K

8-K — CLARIVATE PLC

Accession: 0001764046-26-000085

Filed: 2026-07-06

Period: 2026-07-06

CIK: 0001764046

SIC: 7374 (SERVICES-COMPUTER PROCESSING & DATA PREPARATION)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — clvt-20260706.htm (Primary)

EX-99.1 (ex991lshdivestiturepressre.htm)

EX-99.2 (ex992lshdivestitureinves.htm)

GRAPHIC (ex992lshdivestitureinves001.jpg)

GRAPHIC (ex992lshdivestitureinves002.jpg)

GRAPHIC (ex992lshdivestitureinves003.jpg)

GRAPHIC (ex992lshdivestitureinves004.jpg)

GRAPHIC (ex992lshdivestitureinves005.jpg)

GRAPHIC (ex992lshdivestitureinves006.jpg)

GRAPHIC (ex992lshdivestitureinves007.jpg)

GRAPHIC (ex992lshdivestitureinves008.jpg)

GRAPHIC (ex992lshdivestitureinves009.jpg)

GRAPHIC (ex992lshdivestitureinves010.jpg)

GRAPHIC (ex992lshdivestitureinves011.jpg)

GRAPHIC (ex992lshdivestitureinves012.jpg)

GRAPHIC (ex992lshdivestitureinves013.jpg)

GRAPHIC (ex992lshdivestitureinves014.jpg)

GRAPHIC (ex992lshdivestitureinves015.jpg)

GRAPHIC (ex992lshdivestitureinves016.jpg)

GRAPHIC (ex992lshdivestitureinves017.jpg)

GRAPHIC (ex992lshdivestitureinves018.jpg)

GRAPHIC (ex992lshdivestitureinves019.jpg)

GRAPHIC (ex992lshdivestitureinves020.jpg)

GRAPHIC (ex992lshdivestitureinves021.jpg)

GRAPHIC (ex992lshdivestitureinves022.jpg)

GRAPHIC (ex992lshdivestitureinves023.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: clvt-20260706.htm · Sequence: 1

clvt-20260706

0001764046false00-000000000017640462026-07-062026-07-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 6, 2026

CLARIVATE PLC

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

(State or other jurisdiction of incorporation or organization)

001-38911

(Commission File Number)

N/A

(I.R.S. Employer Identification No.)

70 St. Mary Axe

London

EC3A 8BE

United Kingdom

(Address of Principal Executive Offices)

(44) 207-433-4000

Registrant's telephone number, including area code

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Ordinary Shares, no par value CLVT New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On July 6, 2026, Clarivate Plc (“Clarivate” or the “Company”) announced an agreement to sell its Life Sciences and Healthcare business to an affiliate of Altaris, LLC. The purchase agreement for the transaction includes customary representations, warranties and covenants by the parties. The press release has been furnished with this Current Report on Form 8-K as Exhibit 99.1 and is posted on the investor relations section of the Company’s website (http://ir.clarivate.com/).

The Company will be delivering the investor presentation on the conference call referred to in the press release, and will post to its website supplemental information related to the transaction. The supplemental information that will be posted on the Company’s website has been furnished with this Current Report on Form 8-K as Exhibit 99.2.

The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration or other document pursuant to the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

No. Description

99.1

Press release issued by Clarivate Plc dated July 6, 2026.

99.2

Supplemental Information dated July 6, 2026.

104 Cover page of this Current Report on Form 8-K formatted in Inline XBRL.

FORWARD-LOOKING STATEMENTS

This report includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the anticipated divestiture of our Life Sciences & Healthcare business or any other strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our Life Sciences & Healthcare business, anticipated cost savings, results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign exchange impacts, prospects, growth, strategies, and the markets in which we operate, our financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence (“AI”) on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLARIVATE PLC

Date: July 6, 2026

By: /s/ Jonathan Collins

Name: Jonathan Collins

Title: Executive Vice President & Chief Financial Officer

EX-99.1

Filename: ex991lshdivestiturepressre.htm · Sequence: 2

Document

Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company’s focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments

Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and lowering capital intensity; proceeds to be used to reduce debt

Reaffirms full-year 2026 financial outlook

Conference call and webcast scheduled for 9:00 AM eastern time

London, U.K. July 6, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today announced it has entered into a definitive agreement to divest its Life Sciences & Healthcare (“LS&H”) segment to Altaris LLC, an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, for $600 million.

Following the close of the transaction, Clarivate will be a subscription-first global provider of intelligence solutions, workflow software and tech-enabled services for its leading Academia & Government ("A&G") and Intellectual Property ("IP") segments. Both segments already benefit from deep customer relationships, as well as shared content assets and technology platforms. A&G’s research, education and library solutions propel academic institutions and government organizations forward, and IP’s leading data, software and expertise reshape the way companies create, manage and protect intellectual property. With this sharpened focus, Clarivate will drive sustained value through differentiated insights, workflow solutions and tech-enabled services at scale.

Matti Shem Tov, Chief Executive Officer of Clarivate, said: “We are pleased to have reached this agreement, which is well-aligned with Clarivate's four-pillared Value Creation Plan to optimize our business model, improve our sales execution, accelerate innovation and rationalize our portfolio, all with the goal of unlocking shareholder value. With the complementary nature of A&G’s and IP’s businesses, we will enhance efficiency, sharpen execution, strengthen innovation and grow customer reach. The Company will have a stronger financial profile and more focused portfolio, making it well positioned as a leader in the knowledge and innovation economy and poised to drive sustained value for shareholders, customers and employees."

Jonathan Collins, Executive Vice President and Chief Financial Officer of Clarivate, said: “This strategic divestiture strengthens Clarivate’s financial profile and accelerates our debt reduction plan. Moreover, monetizing the LS&H segment will enhance the quality of our revenue mix, lower capital intensity, and improve margins. The result is a streamlined Company with increased financial flexibility to support long-term growth and disciplined capital allocation.”

Henry Levy, President, Life Sciences & Healthcare, at Clarivate, said: “The LS&H segment integrates deep domain expertise, trusted data assets and strong analytical capabilities to support critical decision-making across the drug and device lifecycle, aiding customers from discovery to commercialization and market access. Under Altaris, the business will be well-positioned to build on its strong foundation and enter its next phase of growth, supported by continued investment and a strong focus on customer impact.”

Transaction Details, Debt Reduction and Timing to Close

Under the terms of the agreement, Clarivate will receive $500 million in cash at closing, $25 million in cash deferred to the completion of a transition services agreement and a $75 million seller note.

The Company intends to use the cash proceeds to reduce debt, strengthening its balance sheet and reinforcing its focus on furthering shareholder value creation.

The transaction is expected to close by the end of the year, subject to customary closing conditions, including regulatory approvals and the expiration of applicable waiting periods.

Reaffirms Full-Year 2026 Financial Outlook

Clarivate reaffirmed its full-year 2026 financial outlook including the LS&H segment results for the full year, which will be classified as discontinued operations starting in the third quarter. The Company expects to update its full-year outlook when the transaction closes. The Company also expects to record an approximately $225 to $250 million non-cash goodwill impairment on the LS&H segment, based on the agreed upon sales price, that will not impact any of the financial metrics in its full-year outlook.

Forward-Looking Statement

The full-year outlook presented below assumes no further acquisitions, divestitures or other unanticipated events.

Full-Year 2026 Financial Outlook

Organic ACV 2.0% to 3.0%

Recurring Organic Revenue Growth 0.75% to 2.25%

Revenues, including discontinued operations $2.30B to $2.42B

Revenues $1.94B to $2.04B

Adjusted EBITDA(1)

$980M to $1.04B

Adjusted EBITDA Margin(1)

42.0% to 43.5%

Adjusted Diluted EPS(1)(2)

$0.70 to $0.80

Free Cash Flow(1)

$365M to $435M

Notes

(1)Non-GAAP measure. Please see “Use of Non-GAAP Financial Measures” and “Reconciliations to Certain Non-GAAP Measures” in this release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this press release.

(2)Adjusted diluted EPS for 2026 is calculated based on approximately 650 million fully diluted adjusted weighted average ordinary shares outstanding.

Conference Call and Webcast

Clarivate will host a conference call and webcast today to discuss the transaction results at 9:00 a.m. Eastern Time. The webcast is open to all interested parties and may include forward-looking information. The webcast will be accessible through the investor relations section of the Company’s website. To join the webcast, please visit https://events.q4inc.com/attendee/434451402.

Interested parties may also access the live audio broadcast. U.S. participants may call 800-715-9871; international participants may call +1 646-307-1963 (long-distance charges will apply). The conference ID number is 4186636.

A replay of the webcast will also be available on https://ir.clarivate.com beginning two hours after the conclusion of the live call.

Advisors

Morgan Stanley & Co. LLC is serving as financial advisor. Davis Polk & Wardwell LLP and Hogan Lovells Cadwalader are serving as legal advisors. Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor.

Use of Non-GAAP Financial Measures

This release contains financial measures that have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted diluted EPS, Free cash flow, and Revenues, including discontinued operations. Non-GAAP financial measures are not recognized terms under GAAP, are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.

We use non-GAAP measures internally in our operational and financial decision-making, to assess the operating performance of our business, to assess performance for employee compensation purposes, and to decide how to allocate resources. We believe that such measures allow us to focus on what we deem to be more reliable indicators of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. Further, these measures can be useful in evaluating our performance against our peer companies because we believe they provide users with valuable insight into key components of our GAAP financial disclosure. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.

Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all.

Forward-Looking Statements

This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the anticipated divestiture of our LS&H business or any other strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our LS&H business, anticipated cost savings, results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign exchange impacts, prospects, growth, strategies, and the markets in which we operate, our financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence (“AI”) on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”).

There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property, and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.

Media Contact:

Amy Bourke-Waite, Senior Director, Communications & Brand

newsroom@clarivate.com

Investor Relations Contact:

Mark Donohue, Vice President, Investor Relations

investor.relations@clarivate.com

Reconciliations to Certain Non-GAAP Measures

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Net income (loss) margin is calculated by dividing Net income (loss) by Revenues. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.

The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the 2026 outlook and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss) margin for the same period:

Year Ending December 31, 2026

(Forecasted)

(In millions); (unaudited) Low High

Net income (loss) $ (461) $ (371)

Provision (benefit) for income taxes 43 48

Depreciation and amortization 786 786

Interest expense, net 238 228

Share-based compensation expense 70 70

Goodwill and intangible asset impairments 250 225

Restructuring costs(1)

25 25

Transaction related costs 35 35

Other (6) (6)

Adjusted EBITDA $ 980 $ 1,040

Net income (loss) margin (19.5) % (15.7) %

Adjusted EBITDA margin 41.5 % 44.0 %

(1) Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan.

Adjusted Diluted EPS

Adjusted net income represents Net income (loss), adjusted to exclude amortization related to acquired intangible assets, share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance and the associated income tax impact of such adjustments.

Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares. The Adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are dilutive.

The following table presents our calculation of Adjusted diluted EPS for the 2026 outlook and reconciles this non-GAAP measure to our Net income (loss) per share for the same period:

Year Ending December 31, 2026

(Forecasted)

(Unaudited) Low High

Net income (loss) per share $ (0.70) $ (0.57)

Amortization related to acquired intangible assets 0.84 0.84

Share-based compensation expense 0.11 0.11

Goodwill and intangible asset impairments 0.38 0.35

Restructuring costs(1)

0.04 0.04

Transaction related costs 0.05 0.05

Other 0.02 0.02

Income tax impact of related adjustments (0.04) (0.04)

Adjusted diluted EPS $ 0.70 $ 0.80

Adjusted weighted average ordinary shares, diluted ~650 million

(1) Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan.

Free Cash Flow

Free cash flow represents Net cash provided by operating activities less Capital expenditures.

The following table presents our calculation of Free cash flow for the 2026 outlook and reconciles this non-GAAP measure to our Net cash provided by operating activities for the same period:

Year Ending December 31, 2026

(Forecasted)

(In millions); (unaudited) Low High

Net cash provided by operating activities $ 615 $ 685

Capital expenditures (250) (250)

Free cash flow $ 365 $ 435

Revenues, Including Discontinued Operations

Revenues, including discontinued operations represents total company revenues including those attributable to discontinued operations, which will begin to be reported in the third quarter for the LS&H segment.

The following table presents our calculation of Revenues, including discontinued operations and reconciles this non-GAAP measure to our Revenues, excluding discontinued operations for the same period:

Year Ending December 31, 2026

(Forecasted)

(In millions); (unaudited) Low High

Revenues, including discontinued operations $ 2,300 $ 2,420

Revenues attributable to discontinued operations (360) (380)

Revenues $ 1,940 $ 2,040

EX-99.2

Filename: ex992lshdivestitureinves.htm · Sequence: 3

ex992lshdivestitureinves

LS&H Divestiture Investor Call July 6, 2026

Safe Harbor Statement and Non-GAAP Financial Measures © 2026 Clarivate. All rights reserved. 2 Forward-Looking Statements This presentation includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. Forward-looking statements included in this presentation include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the anticipated divestiture of our LS&H business or any other strategic transactions we may explore, the anticipated use of proceeds from the divestiture of our LS&H business, anticipated cost savings, results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign exchange impacts, prospects, growth, strategies, and the markets in which we operate, our financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence (“AI”) on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward- looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number of risks, uncertainties, and other important factors (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Factors that may impact such forward-looking statements include, but are not limited to, our ability to compete in the highly competitive industry in which we operate; our ability to maintain high annual renewal rates; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace with or adapt to rapidly changing technology, evolving industry standards, and changing regulatory requirements; reductions in customers’ research budgets or government funding; the success of our Value Creation Plan; our ability to derive fully the anticipated benefits from organic growth, existing or future acquisitions, joint ventures, investments, or dispositions; our exposure to risk from the international scope of our operations; our level of indebtedness; our ability to leverage AI in our products and services; any significant disruption in or unauthorized access to or breaches of our computer systems or those of third parties that we utilize in our operations; other factors beyond our control; and those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

Safe Harbor Statement and Non-GAAP Financial Measures © 2026 Clarivate. All rights reserved. 3 Non-GAAP Financial Measures This presentation contains financial measures that have not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Free Cash Flow, and Free Cash Flow Margin. Non-GAAP financial measures are not recognized terms under GAAP, are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP. We use non-GAAP measures internally in our operational and financial decision-making, to assess the operating performance of our business, to assess performance for employee compensation purposes, and to decide how to allocate resources. We believe that such measures allow us to focus on what we deem to be more reliable indicators of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. Further, these measures can be useful in evaluating our performance against our peer companies because we believe they provide users with valuable insight into key components of our GAAP financial disclosure. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies. Definitions and reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures are provided within the Appendix to this presentation. Our presentation of non- GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all. Industry and Market Data The market data and other statistical information used throughout this presentation are based on industry publications and surveys, public filings, and various government sources. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of the included information. We have not independently verified such third-party information, nor have we ascertained the underlying economic assumptions relied upon in those sources, and we are unable to assure you of the accuracy or completeness of such information contained in this presentation. While we are not aware of any misstatements regarding our market, industry, or similar data presented herein, such data involve risks and uncertainties and are subject to change based on various factors.

Matti Shem Tov Chief Executive Officer Strategic Rationale

Reached Definitive Agreement to Sell LS&H Segment © 2026 Clarivate. All rights reserved. 6 Concluded strategic review in Q1 announcing intention to sell LS&H business LS&H DivestiturePortfolio Composition Definitive agreement reached to sell entire LS&H segment to Altaris LLC Expect transaction to close by year end subject to customary regulatory approvals and closing conditions 1 2025A. Segment Adj. EBITDA – Capital Expenditures Contribution1

Sale Represents Continued Progress on Value Creation Plan Product & Agentic AI Accelerated Innovation Optimize ROI and Support Sales Execution Sales Improved Sales Execution Increase Organic Growth and Achieve Targets Revenue Business Model Optimization Increase Subscription and Re-occurring Revenue Mix Portfolio Solutions Rationalization Unlock Value for Shareholders 7 Value Creation Enablers Talent and Culture Cost Rationalization Enterprise Technology © 2026 Clarivate. All rights reserved. ▲ 900bps Increase in recurring organic revenue mix1, 2 ▲ 160 bps Increase in organic annual contract value growth1 ▲ 16 Major product and AI-powered capabilities released3 ▲ 4 Strategic disposals and divestitures4 1 2024A vs. Midpoint of 2026 Guidance. 2 Subscription + Re-occurring order types. 3 Nov 2024 – May 2026. 4 Announced or completed.

Strategic Move Sharpens Focus and Enhances Financial Profile © 2026 Clarivate. All rights reserved. 8 Focus on Innovative, Leading Business Segments 1 Streamline Operating Model 2 Enhance Financial Profile 3 Reduce Debt and Improve Flexibility 4 Enabling Greater Strategic Clarity, Execution Focus and Financial Flexibility

The New Clarivate | Uniquely Scaled Provider of AI Powered Transformative Intelligence Driving the Knowledge and Innovation Economy © 2026 Clarivate. All rights reserved. 9 Academia & Government Intellectual Property 99% of Top 400 Universities 121M Students and Researchers 96% of Top 50 R&D Companies 10K Intellectual Property Customers 96% Organic revenue generated from proprietary solutions1 Indispensable Market Position Accelerating research with world’s most trusted citation network and credentials via an AI-native platform Web of Science Powering institutional knowledge with market leading workflow platforms Alma Empowering discovery with category defining collections of scholarly content ProQuest Delivering the global standard for patent and trademark intelligence via an AI-native user interface IPOne Enabling end-to-end IP management with gold standard workflow solutions IPfolio Streamlining global patent renewals and administrative services IP Maintenance Intelligence Solutions | Workflow Software | Tech-Enabled Services AI Research Assistants | AI Workflow Agents | AI Ecosystem Access AI Powered Transformative Intelligence 1 FY2025A organic revenue.

Jonathan Collins Chief Financial Officer Financial Implications

Transaction Overview © 2026 Clarivate. All rights reserved. 11 Acquiror Altaris LLC Use of Proceeds Net cash proceeds will be used to retire notes due 2028 and 2029 Timing Expect transaction to close by year end subject to customary regulatory approvals and closing conditions Valuation / Consideration $600m / $525m cash, $75m seller note 10x Adj. EBITDA less Capital Expenditures; ▲ 3x v. CLVT at 7x1 Transaction Details DRG Commercialization Solutions Cortellis R&D Solutions 1 $600m / LS&H Segment 2026T Adj. EBITDA of ~$120m - Capital Spending of ~$60m = 10x; CLVT 3/31 Net Debt of $4.1b + 6/30 Market Capitalization of $1.4b = Enterprise Value of $5.5b / 2026T Adj. EBITDA ~$1,010m – Capital Spending of ~$250m = 7x

LS&H Divestiture Improves Key Financial Metrics and Maintains FCF 12© 2026 Clarivate. All rights reserved. Key Metrics 2026T¹ 2026T Exc. LS&H² Growth / Revenues / Mix • LS&H segment has the highest transactional revenue in portfolio; will increase recurring mix Adj. EBITDA / Margin • LS&H segment has the lowest profit margin in the portfolio; will increase profit margin Free Cash Flow • LS&H segment has the highest capital intensity in the portfolio; will lower capital spend by ~$60m • This year’s FCF guidance now includes ~$35m of transaction costs to complete this divestiture (guidance mid-point included ~$15m to get to signing) • Up front cash proceeds of ~$0.5b will be used to retire notes; will lower cash interest by ~$25m • ~$5m of cash taxes tied to LS&H Revenues ~$2,360 ~$1,990 ▼ ~(370) Adj. EBITDA³ ~$1,010 ~$890 ▼ ~(120) Free Cash Flow³ ~$380 ~$385 ▲ ~+5 1 Mid-point of full-year guidance ranges except FCF, which now contemplates ~$20m of additional post-signing transaction costs (see p17). 2 These measures are illustrative, are not pro forma financial results prepared in accordance with Article 11 of Regulation S-X and have not been audited or reviewed by our independent accounting firm. ³ See the Appendix for a reconciliation of GAAP to Non-GAAP measures. Recurring Organic Growth ~1.5% ~1.5% No Change Recurring Organic Revenue Mix ~89% ~92% ▲ ~+300 bps  Adj. EBITDA Margin³ ~42¾% ~44¾% ▲ ~+200 bps  ~$250 ~$190 ▼ ~(60)Capital Expenditures ~$345 ~$280 ▼ ~(65)1X, Interest, Taxes  FY 2026 Estimated Impact of LS&H Divestiture Free Cash Flow Margin³ ~16% ~19¼% ▲ ~+325 bps   

Proceeds and FCF Generation Enable Retirement of Mid-Term Debt Maturities © 2026 Clarivate. All rights reserved. 13 900 900 775 2,499 2026 2027 2028 2029 2030 2031 Senior Secured Notes Senior Notes Undrawn RCF Term Loan B Debt Maturity Profile ($ millions) Illustrative Deleveraging Path ($ millions) 900 ~500 900 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27 Q3 27 Q4 27 Q1 28 Q2 28 Q3 28 Q4 28 Q1 29 Q2 29 2028 Senior Secured Notes 2029 Senior Notes Net Leverage 4.0x ~3.5x ~3.0x ~2.5x Debt Maturity Profile • Favorable runway with no near-term debt maturities 2028 and 2029 Notes • Proceeds from the LS&H sale will be used to repurchase or retire ~$0.5b of these notes • Like the last three years, expect average quarterly FCF of at least ~$100m over the next three years post- divestiture as FCF contribution from LS&H segment has been negligible • Based on current debt market conditions, intend to use FCF to repurchase or retire the remaining notes in their entirety by their respective maturities

Investment Highlights © 2026 Clarivate. All rights reserved. 14 Transaction Represents Continued VCP Progress and Enhanced Financial Profile Delivering on Value Creation Plan Commitments Improving Predictability Through Revenue Mix  Accelerating Organic Growth  Delivering AI-Driven Innovation  Rationalizing Portfolio With Sale of LS&H  Enhancing Financial Profile With Divestiture Improving Recurring Revenue Mix  Expanding Profit Margin  Lowering Capital Intensity  Maintaining FCF & Reducing Debt 

Q&A Session

Appendix Full Year Guidance and Presentation of Certain Non-GAAP Financial Measures

FY 2026 Guidance Reaffirmed; Assumes Transaction Closes at Year End 17© 2026 Clarivate. All rights reserved. ACV Organic Growth • Likely in lower half of range as LS&H will be inorganic in H2 Recurring Organic Growth • Subscription growth acceleration and stable re-occurring revenues Revenues Incl. Discontinued Ops • Decline over prior year due entirely to strategic disposals; revenue mix likely above range as LS&H moves to inorganic in H2 Adj. EBITDA / Margin / EPS1 • Margin expansion driven by organic growth and cost discipline • EPS growth due to share repurchases Free Cash Flow1 • Likely in lower half of range due to ~$20m of incremental one-time costs to close transaction +50 bps ACV Organic Growth 2% 3% ~2¼% Recurring Organic Revenue Mix3 88% 90% ~92% +400 bps Adj. EBITDA1 $980m $1,040m ~$1,010m +1% Adj. EBITDA Margin1 42% 43½% ~42¾% +200 bps Adj. Diluted EPS1 80₵70₵ ~75₵ +9% Free Cash Flow1 $365m $435m ~$380m +5% (4)% Revenues Including Discontinued Ops1 $2,300m $2,420m ~$2,360m +90 bps Recurring Organic Growth2 ¾% 2¼% ~1½% Current vs. PY 1 See the Appendix for a reconciliation of GAAP to Non-GAAP measures. 2 Subscription + Re-occurring order types. 3 (Subscription + Re-occurring) / Total Revenues excluding disposals. 4 Mid Point included for illustrative purposes only. Mid Point4Guidance Range Current Indication from Transaction Impact

18© 2026 Clarivate. All rights reserved. Presentation of Certain Non-GAAP Financial Measures Adjusted EBITDA and Adjusted EBITDA margin Adjusted EBITDA represents net income (loss) before the provision (benefit) for income taxes, depreciation and amortization, and interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues. Net income (loss) margin is calculated by dividing Net income (loss) by Revenues. Free cash flow and Free cash flow margin Free cash flow represents Net cash provided by (used for) operating activities less capital expenditures. Free cash flow margin is calculated by dividing free cash flow by Revenues. Operating cash flow margin is calculated by dividing Net cash provided by operating activities by revenues. Adjusted net income and Adjusted diluted EPS Adjusted net income represents net income (loss), adjusted to exclude amortization related to acquired intangible assets, share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance and the associated income tax impact of such adjustments. Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares. The adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are dilutive. Revenues, Including Discontinued Operations Revenues, including discontinued operations represents total company revenues including those attributable to discontinued operations, which will begin to be reported in the third quarter for the LS&H segment.

19© 2026 Clarivate. All rights reserved. Year Ending December 31, 2026 (Forecasted) Incl. LS&H Year Ending December 31, 2026 (Forecasted) Excl. LS&H $m Low Mid-Point High Mid-Point Net income (loss) $(461) $(416) $(371) $(126) Provision (benefit) for income taxes 43 46 48 41 Depreciation and amortization 786 786 786 695 Interest expense, net 238 233 228 208 Share-based compensation expense 70 70 70 58 Goodwill and intangible asset impairments 250 238 225 0 Restructuring costs1 25 25 25 20 Transaction related costs 35 35 35 0 Other (6) (6) (6) (6) Adjusted EBITDA $980 $1,010 $1,040 $890 Net income (loss) margin (19.5)% (17.6)% (15.7)% (6.3)% Adjusted EBITDA margin 41.5% 42.75% 44.0% 44.75% 1 For the 2026 outlook, reflects restructuring costs expected to be incurred associated with the Value Creation Plan. Reconciliation of Non-GAAP Financial Measures – 2026 Outlook Net income (loss) to Adjusted EBITDA and Adjusted EBITDA margin

20 Year Ending December 31, 2026 (Forecasted) Incl. LS&H Year Ending December 31, 2026 (Forecasted) Excl. LS&H $m Low Current Indication High Current Indication Net cash provided by operating activities $615 $630 $685 $575 Capital expenditures (250) (250) (250) (190) Free cash flow $365 $380 $435 $385 Operating cash flow margin 26.7% 26.7% 28.3% 28.9% Free cash flow margin 15.9% 16.0% 18.0% 19.25% © 2026 Clarivate. All rights reserved. Reconciliation of Non-GAAP Financial Measures – 2026 Outlook Net cash provided by operating activities to Free cash flow and Free cash flow margin

21© 2026 Clarivate. All rights reserved. Year Ending December 31, 2026 (Forecasted) $m Low High Net income (loss) per share $(0.70) $(0.57) Amortization related to acquired intangible assets 0.84 0.84 Share-based compensation expense 0.11 0.11 Goodwill and intangible asset impairments 0.38 0.35 Restructuring costs1 0.04 0.04 Transaction related costs 0.05 0.05 Other 0.02 0.02 Income tax impact of related adjustments (0.04) (0.04) Adjusted diluted EPS $0.70 $0.80 Adjusted weighted average ordinary shares, diluted ~650 million Reconciliation of Non-GAAP Financial Measures – 2026 Outlook 1 Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan. Net income (loss) per fully diluted weighted shares outstanding to Adjusted diluted EPS

22 Year Ending December 31, 2026 (Forecasted) $m Low High Revenues, including discontinued operations $2,300 $2,420 Revenues attributable to discontinued operations (360) (380) Revenues $1,940 $2,040 © 2026 Clarivate. All rights reserved. Reconciliation of Non-GAAP Financial Measures – 2026 Outlook Revenues, Including Discontinued Operations to Revenues

© 2026 Clarivate Clarivate and its logo, as well as all other trademarks used herein, are trademarks of their respective owners and used under license. About Clarivate Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

GRAPHIC

Filename: ex992lshdivestitureinves001.jpg · Sequence: 7

Binary file (136794 bytes)

Download ex992lshdivestitureinves001.jpg

GRAPHIC

Filename: ex992lshdivestitureinves002.jpg · Sequence: 8

Binary file (277220 bytes)

Download ex992lshdivestitureinves002.jpg

GRAPHIC

Filename: ex992lshdivestitureinves003.jpg · Sequence: 9

Binary file (234391 bytes)

Download ex992lshdivestitureinves003.jpg

GRAPHIC

Filename: ex992lshdivestitureinves004.jpg · Sequence: 10

Binary file (35651 bytes)

Download ex992lshdivestitureinves004.jpg

GRAPHIC

Filename: ex992lshdivestitureinves005.jpg · Sequence: 11

Binary file (47276 bytes)

Download ex992lshdivestitureinves005.jpg

GRAPHIC

Filename: ex992lshdivestitureinves006.jpg · Sequence: 12

Binary file (79404 bytes)

Download ex992lshdivestitureinves006.jpg

GRAPHIC

Filename: ex992lshdivestitureinves007.jpg · Sequence: 13

Binary file (98027 bytes)

Download ex992lshdivestitureinves007.jpg

GRAPHIC

Filename: ex992lshdivestitureinves008.jpg · Sequence: 14

Binary file (71649 bytes)

Download ex992lshdivestitureinves008.jpg

GRAPHIC

Filename: ex992lshdivestitureinves009.jpg · Sequence: 15

Binary file (133520 bytes)

Download ex992lshdivestitureinves009.jpg

GRAPHIC

Filename: ex992lshdivestitureinves010.jpg · Sequence: 16

Binary file (47756 bytes)

Download ex992lshdivestitureinves010.jpg

GRAPHIC

Filename: ex992lshdivestitureinves011.jpg · Sequence: 17

Binary file (87221 bytes)

Download ex992lshdivestitureinves011.jpg

GRAPHIC

Filename: ex992lshdivestitureinves012.jpg · Sequence: 18

Binary file (139156 bytes)

Download ex992lshdivestitureinves012.jpg

GRAPHIC

Filename: ex992lshdivestitureinves013.jpg · Sequence: 19

Binary file (113744 bytes)

Download ex992lshdivestitureinves013.jpg

GRAPHIC

Filename: ex992lshdivestitureinves014.jpg · Sequence: 20

Binary file (88578 bytes)

Download ex992lshdivestitureinves014.jpg

GRAPHIC

Filename: ex992lshdivestitureinves015.jpg · Sequence: 21

Binary file (25293 bytes)

Download ex992lshdivestitureinves015.jpg

GRAPHIC

Filename: ex992lshdivestitureinves016.jpg · Sequence: 22

Binary file (42594 bytes)

Download ex992lshdivestitureinves016.jpg

GRAPHIC

Filename: ex992lshdivestitureinves017.jpg · Sequence: 23

Binary file (134974 bytes)

Download ex992lshdivestitureinves017.jpg

GRAPHIC

Filename: ex992lshdivestitureinves018.jpg · Sequence: 24

Binary file (129849 bytes)

Download ex992lshdivestitureinves018.jpg

GRAPHIC

Filename: ex992lshdivestitureinves019.jpg · Sequence: 25

Binary file (91759 bytes)

Download ex992lshdivestitureinves019.jpg

GRAPHIC

Filename: ex992lshdivestitureinves020.jpg · Sequence: 26

Binary file (72510 bytes)

Download ex992lshdivestitureinves020.jpg

GRAPHIC

Filename: ex992lshdivestitureinves021.jpg · Sequence: 27

Binary file (80804 bytes)

Download ex992lshdivestitureinves021.jpg

GRAPHIC

Filename: ex992lshdivestitureinves022.jpg · Sequence: 28

Binary file (56684 bytes)

Download ex992lshdivestitureinves022.jpg

GRAPHIC

Filename: ex992lshdivestitureinves023.jpg · Sequence: 29

Binary file (106451 bytes)

Download ex992lshdivestitureinves023.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 43

v3.26.1

Document and Entity Information Document

Jul. 06, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Jul. 06, 2026

Entity Registrant Name

CLARIVATE PLC

Entity Incorporation, State or Country Code

Entity File Number

001-38911

Entity Tax Identification Number

00-0000000

Entity Address, Address Line One

70 St. Mary Axe

Entity Address, City or Town

London

Entity Address, Postal Zip Code

EC3A 8BE

Entity Address, Country

City Area Code

Local Phone Number

207-433-4000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Ordinary Shares, no par value

Trading Symbol

CLVT

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001764046

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration